A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. / Ohrstrom, Caroline C.; Hansen, Dorte L.; Kielgast, Urd Lynge; Hartmann, Bolette; Holst, Jens Juul; Worm, Dorte.

I: Obesity Surgery, Bind 30, 2020, s. 1605-1610.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ohrstrom, CC, Hansen, DL, Kielgast, UL, Hartmann, B, Holst, JJ & Worm, D 2020, 'A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals', Obesity Surgery, bind 30, s. 1605-1610. https://doi.org/10.1007/s11695-019-04248-x

APA

Ohrstrom, C. C., Hansen, D. L., Kielgast, U. L., Hartmann, B., Holst, J. J., & Worm, D. (2020). A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. Obesity Surgery, 30, 1605-1610. https://doi.org/10.1007/s11695-019-04248-x

Vancouver

Ohrstrom CC, Hansen DL, Kielgast UL, Hartmann B, Holst JJ, Worm D. A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. Obesity Surgery. 2020;30:1605-1610. https://doi.org/10.1007/s11695-019-04248-x

Author

Ohrstrom, Caroline C. ; Hansen, Dorte L. ; Kielgast, Urd Lynge ; Hartmann, Bolette ; Holst, Jens Juul ; Worm, Dorte. / A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. I: Obesity Surgery. 2020 ; Bind 30. s. 1605-1610.

Bibtex

@article{5a0db06450904d6896709e2e4ac3d1c8,
title = "A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals",
abstract = "Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.",
keywords = "Gastric bypass, Hypoglycemia, Hyperglycemia, Pasireotide, Somatostatin analogs",
author = "Ohrstrom, {Caroline C.} and Hansen, {Dorte L.} and Kielgast, {Urd Lynge} and Bolette Hartmann and Holst, {Jens Juul} and Dorte Worm",
year = "2020",
doi = "10.1007/s11695-019-04248-x",
language = "English",
volume = "30",
pages = "1605--1610",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

AU - Ohrstrom, Caroline C.

AU - Hansen, Dorte L.

AU - Kielgast, Urd Lynge

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Worm, Dorte

PY - 2020

Y1 - 2020

N2 - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.

AB - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.

KW - Gastric bypass

KW - Hypoglycemia

KW - Hyperglycemia

KW - Pasireotide

KW - Somatostatin analogs

U2 - 10.1007/s11695-019-04248-x

DO - 10.1007/s11695-019-04248-x

M3 - Journal article

C2 - 31709494

VL - 30

SP - 1605

EP - 1610

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

ER -

ID: 230692191